je.st
news
Tag: tumor
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
2014-09-02 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
types
studies
Mercks Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
2014-05-14 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-nave and treated settings; data included in ASCO Press Program First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer First presentation of findings of MK-3475 in recurrent/metastatic head and neck cancer WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data for the companys investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer, are scheduled to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on May 30 June 3, 2014. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
SRI International Announces PDCellX Xenograft Tumor Model Services To Accelerate Cancer Drug Research
2014-04-30 07:22:26| drugdiscoveryonline News Articles
SRI International has announced the availability of its PDCellX™ xenograft tumor model services for testing the activity of potential cancer therapeutics
Tags: services
international
research
model
Pfizer drug doubles time to breast cancer tumor growth in trial
2014-04-06 22:56:50| Biotech - Topix.net
Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.
N-of-One and BioDiscovery Partner to Deliver Tumor Genomics Analysis and Interpretation Platform
2014-03-25 05:00:00| Industrial Newsroom - All News for Today
Partnership Equips Laboratories and Oncologists with a Foundation for Genomic Data Analysis through to Therapeutic Options<br /> <br /> Hawthorne, CA and Lexington, MA – BioDiscovery, Inc., a leader in DNA structural variant analysis laboratory software for copy number (CNV) and sequence variation, and N-of-One, the leading provider of molecular interpretation and therapeutic strategies for precision medicine in oncology, today announced a partnership to jointly provide integrated ...This story is related to the following:Laboratory and Research Supplies and EquipmentSearch for suppliers of: Data Analysis Software | Health Care Software |
Tags: partner
analysis
platform
deliver